Hit or Miss: Companies with 2023 Readouts & Launches to Keep in Focus

Our second panel, “Hit or Miss: Companies with 2023 Readouts & Launches to Keep in Focus,” featured Brian Kevany, CTO & Head of Research of Abeona Therapeutics, Scott Robertson, CFO & CBO of DICE Therapeutics, Raul Collazo PhD, VP of Medical Affairs of Connect BioPharma Holdings, Dr. Par Nijhawan, CEO of Edesa Biotech, Inc., Matthias Bodenstedt, CFO of MoonLake Immunotherapeutics (NASDAQ: MLTX), and David Domzalski, President & CEO of VYNE Therapeutics Inc. The panel was moderated by Cantor’s Prakhar Agrawal.

The companies highlighted the clinical trial data for their respective pipeline drugs, the unmet needs targeted by their drugs, differentiation relative to competitors, and the key factors underappreciated by investors heading into 2023.

#Cantor #Cantorfitzgerald #Cantorhealthcare #Cantorconferenceseries #Dermatology #Opthalmology #Medtech #Diagnostic